Previous 10 | Next 10 |
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
2024-02-23 03:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights PR Newswire ROCKVILLE, Md. , Feb. 21, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will...
2024-02-19 20:42:02 ET Summary Age-related macular degeneration (AMD) is a leading cause of vision loss and blindness, with wet AMD being a more severe form. Current treatment for wet AMD involves frequent anti-VEGF injections, but there is a need for therapies with less frequent ...
2024-02-12 04:47:00 ET Summary For the week just past, the S&P 500 was up 1.4%. Even though Magnificent 7 stocks continue to lead the market higher, market participation is broadening out, which is a healthy sign. The ProShares Bitcoin Strategy ETF took the top spot on the...
2024-02-07 12:48:15 ET More on Regenxbio Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips Seeking Alpha’s Quant Rating on Regenxbio Historical earnings data for Regenxbio Financial information for Regenxbio Read the fu...
REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint PR Newswire Results support BLA submission in 2024 using the accelerated approval pathway Primary endpoint of patients achieving reduction in CSF biomarker of MPS II di...
REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial PR Newswire Completed enrollment in cohort 2 of the Phase I/II AFFINITY DUCHENNE ® trial of RGX-202, a potential one-time AAV Therapeutic f...
REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024 PR Newswire Pivotal topline results from the CAMPSIITE ® trial of RGX-121 for the treatment of MPS II to be presented Conference call Wednesday, February 7, 4:30 p.m. ET ...
2024-01-30 09:20:23 ET Summary AbbVie Inc.'s revenues have fallen in 2023 due to the expiration of patents for its best-selling drug Humira, but the decline has not been as severe as expected. AbbVie's share price has grown by 11% in the past six months and over 110% in the past f...
News, Short Squeeze, Breakout and More Instantly...
2024-05-13 17:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights PR Newswire Company remains on track for its first BLA filing in 2024 and is accelerating progress toward pivotal trial initiation for Duchenne (H2 2024) and diabetic retinopathy (H1 202...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...